[go: up one dir, main page]

AR124083A2 - Nuevo inhibidor de sglt1 - Google Patents

Nuevo inhibidor de sglt1

Info

Publication number
AR124083A2
AR124083A2 ARP210103177A ARP210103177A AR124083A2 AR 124083 A2 AR124083 A2 AR 124083A2 AR P210103177 A ARP210103177 A AR P210103177A AR P210103177 A ARP210103177 A AR P210103177A AR 124083 A2 AR124083 A2 AR 124083A2
Authority
AR
Argentina
Prior art keywords
new
sglt1 inhibitor
sglt1
inhibitor
hydrate
Prior art date
Application number
ARP210103177A
Other languages
English (en)
Inventor
Susan Marie Reutzel-Edens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR124083A2 publication Critical patent/AR124083A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula (1) o hidrato del mismo.
ARP210103177A 2013-11-08 2021-11-17 Nuevo inhibidor de sglt1 AR124083A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361901488P 2013-11-08 2013-11-08

Publications (1)

Publication Number Publication Date
AR124083A2 true AR124083A2 (es) 2023-02-08

Family

ID=51982747

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140104010A AR098670A1 (es) 2013-11-08 2014-10-24 Inhibidor de sglt1
ARP210103177A AR124083A2 (es) 2013-11-08 2021-11-17 Nuevo inhibidor de sglt1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140104010A AR098670A1 (es) 2013-11-08 2014-10-24 Inhibidor de sglt1

Country Status (35)

Country Link
US (1) US9573970B2 (es)
EP (1) EP3066108B1 (es)
JP (1) JP6197113B2 (es)
KR (1) KR101858881B1 (es)
CN (1) CN105705509B (es)
AP (1) AP2016009180A0 (es)
AR (2) AR098670A1 (es)
AU (1) AU2014347065B2 (es)
CA (1) CA2925128C (es)
CL (1) CL2016000791A1 (es)
CR (1) CR20160165A (es)
CY (1) CY1121096T1 (es)
DK (1) DK3066108T3 (es)
DO (1) DOP2016000067A (es)
EA (1) EA028801B1 (es)
ES (1) ES2703944T3 (es)
HR (1) HRP20182061T1 (es)
IL (1) IL244899B (es)
JO (1) JO3485B1 (es)
LT (1) LT3066108T (es)
MA (1) MA39019A1 (es)
MX (1) MX368174B (es)
MY (1) MY192242A (es)
NZ (1) NZ718118A (es)
PE (1) PE20160884A1 (es)
PH (1) PH12016500851B1 (es)
PL (1) PL3066108T3 (es)
PT (1) PT3066108T (es)
RS (1) RS58050B1 (es)
SI (1) SI3066108T1 (es)
SV (1) SV2016005190A (es)
TN (1) TN2016000112A1 (es)
TW (1) TWI655198B (es)
UA (1) UA118767C2 (es)
WO (1) WO2015069541A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3065386A1 (en) * 2017-06-12 2018-12-20 Lignamed, Llc Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229581B1 (en) 1999-08-31 2014-02-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002098893A1 (en) 2001-05-30 2002-12-12 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
AU2003254847B2 (en) * 2002-08-08 2009-06-04 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
CN100351263C (zh) * 2002-08-08 2007-11-28 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
BRPI0711949A2 (pt) * 2006-05-19 2012-01-17 Taisho Pharmaceutical Co., Ltd. composto c-fenil glicitol
RU2482122C2 (ru) 2007-12-27 2013-05-20 Киссеи Фармасьютикал Ко., Лтд. Моносебацинат производного пиразола
AU2010216634B2 (en) 2009-02-23 2014-07-10 Taisho Pharmaceutical Co., Ltd. 4 -isopropylphenyl glucitol compounds as SGLT1 inhibitors
BR112012007349A2 (pt) * 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
PH12016500851A1 (en) 2016-06-20
WO2015069541A1 (en) 2015-05-14
EA201690749A1 (ru) 2016-08-31
TWI655198B (zh) 2019-04-01
AP2016009180A0 (en) 2016-04-30
CL2016000791A1 (es) 2016-11-11
JO3485B1 (ar) 2020-07-05
DK3066108T3 (da) 2019-01-02
NZ718118A (en) 2017-11-24
CR20160165A (es) 2016-06-08
MA39019A1 (fr) 2017-04-28
SI3066108T1 (sl) 2018-12-31
SV2016005190A (es) 2018-11-01
AU2014347065A1 (en) 2016-04-07
HRP20182061T1 (hr) 2019-02-08
US20160215011A1 (en) 2016-07-28
MY192242A (en) 2022-08-10
EA028801B1 (ru) 2017-12-29
IL244899B (en) 2019-10-31
AR098670A1 (es) 2016-06-08
UA118767C2 (uk) 2019-03-11
RS58050B1 (sr) 2019-02-28
MX368174B (es) 2019-09-23
KR20160067157A (ko) 2016-06-13
TN2016000112A1 (en) 2017-07-05
PT3066108T (pt) 2018-11-29
AU2014347065B2 (en) 2016-09-29
KR101858881B1 (ko) 2018-05-16
MX2016005999A (es) 2016-07-22
CA2925128A1 (en) 2015-05-14
CA2925128C (en) 2017-10-17
DOP2016000067A (es) 2016-04-15
CY1121096T1 (el) 2019-12-11
PL3066108T3 (pl) 2019-03-29
TW201609783A (zh) 2016-03-16
IL244899A0 (en) 2016-05-31
EP3066108A1 (en) 2016-09-14
LT3066108T (lt) 2019-01-25
PE20160884A1 (es) 2016-09-10
CN105705509B (zh) 2018-12-04
JP6197113B2 (ja) 2017-09-13
CN105705509A (zh) 2016-06-22
ES2703944T3 (es) 2019-03-13
US9573970B2 (en) 2017-02-21
EP3066108B1 (en) 2018-10-24
PH12016500851B1 (en) 2020-02-19
JP2016539099A (ja) 2016-12-15

Similar Documents

Publication Publication Date Title
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CR20150541A (es) Compuestos y composiciones nuevos para la inhibición de fasn
MX378288B (es) Inhibidores de pirimidina del fgfr4.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
MA39843A (fr) Pyridine-2-amides utiles comme agonistes de cb2
AR095097A1 (es) Compuestos de fenoxietoxi
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
AR124083A2 (es) Nuevo inhibidor de sglt1
MX2015014728A (es) Sintesis de inhibidores de beta secretasa (bace).
MX2016007982A (es) Nuevo compuesto para el tratamiento de hipoglucemia severa.
MX2016007984A (es) Nuevo compuesto para el tratamiento de hipoglucemia severa.
CU20130092A7 (es) Nuevo procedimiento para la síntesis de la agomelatina
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt

Legal Events

Date Code Title Description
FB Suspension of granting procedure